Davion Healthcare (NASDAQ:DAVI) Stock Rating Upgraded by Wall Street Zen

Davion Healthcare (NASDAQ:DAVI) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Davion Healthcare Stock Down 37.5%

NASDAQ DAVI opened at $1.68 on Friday. Davion Healthcare has a one year low of $1.65 and a one year high of $12.30.

About Davion Healthcare

Davion Healthcare Plc is a digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments. The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion Healthcare Plc is based in DUBLIN.